J.P. Morgan analyst David Adlington maintained a Buy rating on Siemens Healthineers AG on Monday, setting a price target of EUR54.4, which is approximately 23.36% above the present share price of $52.5.
Adlington expects Siemens Healthineers AG to post earnings per share (EPS) of $0.41 for the second quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Siemens Healthineers AG, with an average price target of $63.9.
The analysts price targets range from a high of $67.86 to a low of $55.95.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $3.97 billion and a net profit of $595 million. The company's market cap is $63.68 billion.
According to TipRanks.com, J.P. Morgan analyst David Adlington is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -3.0% and a 40.24% success rate.
Siemens Healthineers AG operates as a holding company. The company intends to operate the digital services business. It operates through the following business segments: Imaging, Diagnotics, and Advanced Therapies. The Imaging segment offers diagnostic imaging products and a broad portfolio of advanced imaging and ultrasound systems and solutions. The Diagnostics segment offers products, services and solutions, including a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Advanced Therapies is a supplier of advanced therapy products, services and solutions to the therapy departments of healthcare providers. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Erlangen, Germany.